World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders
CONCLUSION: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.PMID:37350265 | DOI:10.1080/15622975.2023.2179663 (Source: The World Journal of Biological Psychiatry)
Source: The World Journal of Biological Psychiatry - June 23, 2023 Category: Psychiatry Authors: Hubertus Himmerich Yael Doreen Lewis Chiara Conti Hiba Mutwalli Andreas Karwautz Jan Magnus Sj ögren Mar ía Mercedes Uribe Isaza Marta Tyszkiewicz-Nwafor Martin Aigner Susan L McElroy Janet Treasure Siegfried Kasper WFSBP Task Force on Eating Disorders Source Type: research
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders
CONCLUSION: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.PMID:37350265 | DOI:10.1080/15622975.2023.2179663 (Source: The World Journal of Biological Psychiatry)
Source: The World Journal of Biological Psychiatry - June 23, 2023 Category: Psychiatry Authors: Hubertus Himmerich Yael Doreen Lewis Chiara Conti Hiba Mutwalli Andreas Karwautz Jan Magnus Sj ögren Mar ía Mercedes Uribe Isaza Marta Tyszkiewicz-Nwafor Martin Aigner Susan L McElroy Janet Treasure Siegfried Kasper WFSBP Task Force on Eating Disorders Source Type: research
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders
CONCLUSION: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.PMID:37350265 | DOI:10.1080/15622975.2023.2179663 (Source: The World Journal of Biological Psychiatry)
Source: The World Journal of Biological Psychiatry - June 23, 2023 Category: Psychiatry Authors: Hubertus Himmerich Yael Doreen Lewis Chiara Conti Hiba Mutwalli Andreas Karwautz Jan Magnus Sj ögren Mar ía Mercedes Uribe Isaza Marta Tyszkiewicz-Nwafor Martin Aigner Susan L McElroy Janet Treasure Siegfried Kasper WFSBP Task Force on Eating Disorders Source Type: research
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders
CONCLUSION: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.PMID:37350265 | DOI:10.1080/15622975.2023.2179663 (Source: The World Journal of Biological Psychiatry)
Source: The World Journal of Biological Psychiatry - June 23, 2023 Category: Psychiatry Authors: Hubertus Himmerich Yael Doreen Lewis Chiara Conti Hiba Mutwalli Andreas Karwautz Jan Magnus Sj ögren Mar ía Mercedes Uribe Isaza Marta Tyszkiewicz-Nwafor Martin Aigner Susan L McElroy Janet Treasure Siegfried Kasper WFSBP Task Force on Eating Disorders Source Type: research
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders
CONCLUSION: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.PMID:37350265 | DOI:10.1080/15622975.2023.2179663 (Source: The World Journal of Biological Psychiatry)
Source: The World Journal of Biological Psychiatry - June 23, 2023 Category: Psychiatry Authors: Hubertus Himmerich Yael Doreen Lewis Chiara Conti Hiba Mutwalli Andreas Karwautz Jan Magnus Sj ögren Mar ía Mercedes Uribe Isaza Marta Tyszkiewicz-Nwafor Martin Aigner Susan L McElroy Janet Treasure Siegfried Kasper WFSBP Task Force on Eating Disorders Source Type: research
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders
CONCLUSION: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.PMID:37350265 | DOI:10.1080/15622975.2023.2179663 (Source: The World Journal of Biological Psychiatry)
Source: The World Journal of Biological Psychiatry - June 23, 2023 Category: Psychiatry Authors: Hubertus Himmerich Yael Doreen Lewis Chiara Conti Hiba Mutwalli Andreas Karwautz Jan Magnus Sj ögren Mar ía Mercedes Uribe Isaza Marta Tyszkiewicz-Nwafor Martin Aigner Susan L McElroy Janet Treasure Siegfried Kasper WFSBP Task Force on Eating Disorders Source Type: research
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders
CONCLUSION: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.PMID:37350265 | DOI:10.1080/15622975.2023.2179663 (Source: The World Journal of Biological Psychiatry)
Source: The World Journal of Biological Psychiatry - June 23, 2023 Category: Psychiatry Authors: Hubertus Himmerich Yael Doreen Lewis Chiara Conti Hiba Mutwalli Andreas Karwautz Jan Magnus Sj ögren Mar ía Mercedes Uribe Isaza Marta Tyszkiewicz-Nwafor Martin Aigner Susan L McElroy Janet Treasure Siegfried Kasper WFSBP Task Force on Eating Disorders Source Type: research
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders
CONCLUSION: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.PMID:37350265 | DOI:10.1080/15622975.2023.2179663 (Source: The World Journal of Biological Psychiatry)
Source: The World Journal of Biological Psychiatry - June 23, 2023 Category: Psychiatry Authors: Hubertus Himmerich Yael Doreen Lewis Chiara Conti Hiba Mutwalli Andreas Karwautz Jan Magnus Sj ögren Mar ía Mercedes Uribe Isaza Marta Tyszkiewicz-Nwafor Martin Aigner Susan L McElroy Janet Treasure Siegfried Kasper WFSBP Task Force on Eating Disorders Source Type: research
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders
CONCLUSION: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.PMID:37350265 | DOI:10.1080/15622975.2023.2179663 (Source: The World Journal of Biological Psychiatry)
Source: The World Journal of Biological Psychiatry - June 23, 2023 Category: Psychiatry Authors: Hubertus Himmerich Yael Doreen Lewis Chiara Conti Hiba Mutwalli Andreas Karwautz Jan Magnus Sj ögren Mar ía Mercedes Uribe Isaza Marta Tyszkiewicz-Nwafor Martin Aigner Susan L McElroy Janet Treasure Siegfried Kasper WFSBP Task Force on Eating Disorders Source Type: research
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders
CONCLUSION: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.PMID:37350265 | DOI:10.1080/15622975.2023.2179663 (Source: The World Journal of Biological Psychiatry)
Source: The World Journal of Biological Psychiatry - June 23, 2023 Category: Psychiatry Authors: Hubertus Himmerich Yael Doreen Lewis Chiara Conti Hiba Mutwalli Andreas Karwautz Jan Magnus Sj ögren Mar ía Mercedes Uribe Isaza Marta Tyszkiewicz-Nwafor Martin Aigner Susan L McElroy Janet Treasure Siegfried Kasper WFSBP Task Force on Eating Disorders Source Type: research
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders
CONCLUSION: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.PMID:37350265 | DOI:10.1080/15622975.2023.2179663 (Source: The World Journal of Biological Psychiatry)
Source: The World Journal of Biological Psychiatry - June 23, 2023 Category: Psychiatry Authors: Hubertus Himmerich Yael Doreen Lewis Chiara Conti Hiba Mutwalli Andreas Karwautz Jan Magnus Sj ögren Mar ía Mercedes Uribe Isaza Marta Tyszkiewicz-Nwafor Martin Aigner Susan L McElroy Janet Treasure Siegfried Kasper WFSBP Task Force on Eating Disorders Source Type: research
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders
CONCLUSION: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.PMID:37350265 | DOI:10.1080/15622975.2023.2179663 (Source: The World Journal of Biological Psychiatry)
Source: The World Journal of Biological Psychiatry - June 23, 2023 Category: Psychiatry Authors: Hubertus Himmerich Yael Doreen Lewis Chiara Conti Hiba Mutwalli Andreas Karwautz Jan Magnus Sj ögren Mar ía Mercedes Uribe Isaza Marta Tyszkiewicz-Nwafor Martin Aigner Susan L McElroy Janet Treasure Siegfried Kasper WFSBP Task Force on Eating Disorders Source Type: research
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders
CONCLUSION: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.PMID:37350265 | DOI:10.1080/15622975.2023.2179663 (Source: The World Journal of Biological Psychiatry)
Source: The World Journal of Biological Psychiatry - June 23, 2023 Category: Psychiatry Authors: Hubertus Himmerich Yael Doreen Lewis Chiara Conti Hiba Mutwalli Andreas Karwautz Jan Magnus Sj ögren Mar ía Mercedes Uribe Isaza Marta Tyszkiewicz-Nwafor Martin Aigner Susan L McElroy Janet Treasure Siegfried Kasper WFSBP Task Force on Eating Disorders Source Type: research
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders
CONCLUSION: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.PMID:37350265 | DOI:10.1080/15622975.2023.2179663 (Source: The World Journal of Biological Psychiatry)
Source: The World Journal of Biological Psychiatry - June 23, 2023 Category: Psychiatry Authors: Hubertus Himmerich Yael Doreen Lewis Chiara Conti Hiba Mutwalli Andreas Karwautz Jan Magnus Sj ögren Mar ía Mercedes Uribe Isaza Marta Tyszkiewicz-Nwafor Martin Aigner Susan L McElroy Janet Treasure Siegfried Kasper WFSBP Task Force on Eating Disorders Source Type: research
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders
CONCLUSION: In BN, fluoxetine, and topiramate, and in BED, LDX and topiramate can be recommended. Despite the published evidence, olanzapine and topiramate have not received marketing authorisation for use in EDs from any medicine regulatory agency.PMID:37350265 | DOI:10.1080/15622975.2023.2179663 (Source: The World Journal of Biological Psychiatry)
Source: The World Journal of Biological Psychiatry - June 23, 2023 Category: Psychiatry Authors: Hubertus Himmerich Yael Doreen Lewis Chiara Conti Hiba Mutwalli Andreas Karwautz Jan Magnus Sj ögren Mar ía Mercedes Uribe Isaza Marta Tyszkiewicz-Nwafor Martin Aigner Susan L McElroy Janet Treasure Siegfried Kasper WFSBP Task Force on Eating Disorders Source Type: research
